se gb

Athera to present at AngloNordic Biotech Conference in London

London, United Kingdom, 5 May 2011 – Athera CEO Carina Schmidt is today an invited speaker at the AngloNordic Biotech Conference. The Anglo-Nordic region continues to be one of the fastest growing biotech regions in the world. Now entering the eighth year, the Anglonordic Biotech Conference provides an opportunity to meet contributors to this success. The audience is invited professionals of pharmaceutical companies and venture capital firms. Ms Schmidt will present the investment opportunity Athera, part of Karolinska Development AB (publ) portfolio, in the Aescap Venture Investment Room.  

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.

In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio. www.athera.se


For further Information:


Athera Biotechnologies AB (publ)
Chief Executive Officer
Carina Schmidt
Tel +46 761938190
c.schmidt@athera.se

2011-05-05